SecBot SecBot

Nucleic Acid Standards for Biosecurity Act

H.R. 3029 Rep. Andrea Salinas (D-OR-6) Passed House
  1. Introduced Apr 28
  2. Committee Apr 28
  3. Passed House Jul 20
  4. Passed Senate Next
  5. To President Not yet
  6. Law Not yet
Where it stands
Passed House, Jul 20, 2026Next: Senate vote
99d ago Jul 21, 2026: Received in the Senate and Read twice and referred to the Committee on Commerce, Science, and Transportation.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
1company, 1 filing
Member trades
0trades in the last 90 days
None in these companies
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

1 company
Companies by sector
Biotech & Pharma 1
Search all 1 companies, their asks and price moves Subscribe

Summary

Nucleic Acid Standards for Biosecurity Act

Full summary5 paragraphs

This bill explicitly requires the National Institute of Standards and Technology (NIST) to support the development of best practices and technical standards for nucleic acid synthesis.

Nucleic acids, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), carry genetic information within cells. Nucleic acid synthesis is the process of designing and creating custom nucleic acids; it is used in the development of medications and agricultural products. However, this technology also poses a risk of misuse (e.g., the intentional or unintentional creation of dangerous biological agents).

The bill requires NIST to carry out measurement research to support the development and improvement of biosecurity best practices and technical standards related to nucleic acid synthesis. This effort must address specified topics including nucleic acid synthesis screening, operational security, and conformity assessment. (A 2023 executive order titled Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence directed NIST to develop and refine similar specifications and best practices for use by synthetic nucleic acid providers. NIST's work on this topic is ongoing.)

In carrying out this effort, NIST must convene stakeholders to develop and periodically update consensus priorities and best practices for synthetic nucleic acid screening mechanisms. Within a specified period, NIST must submit a summary of the stakeholder group’s findings to Congress.

NIST must also take steps to advance risk management best practices and technical standards for engineering biology and biomanufacturing, including with respect to risks associated with the use of artificial intelligence.

Library of Congress summary, Apr 28, 2025

Summary versions
  • Introduced in HouseApr 28, 2025

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.